The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
Open accessAbstract
Intrinsic and evasive antiangiogenic drug (AAD) resistance is frequently developed in cancer patients, and molecular mechanisms underlying AAD resistance remain largely unknown. Here we describe AAD-triggered, lipid-dependent metabolic reprogramming as an alternative mechanism of AAD resistance. Unexpectedly, tumor angiogenesis in adipose and non-adipose environments is equally sensitive to AAD treatment. AAD-treated tumors in adipose environment show accelerated growth rates in the presence of a minimal number of microvessels. Mechanistically, AAD-induced tumor hypoxia initiates the fatty acid oxidation metabolic reprogramming and increases uptake of free fatty acid (FFA) that stimulates cancer cell proliferation. Inhibition of carnitine palmitoyl transferase 1A (CPT1) significantly compromises the FFA-induced cell proliferation. Genetic and pharmacological loss of CPT1 function sensitizes AAD therapeutic efficacy and enhances its anti-tumor effects. Together, we propose an effective cancer therapy concept by combining drugs that target angiogenesis and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Angiogenesis modulates adipogenesis and obesity
Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32239 · Cited by 736
Self-citationInhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Self-citationBensaad, K., Favaro, E., Lewis, C. A., Peck, B., Lord, S., Collins, J. M., Pinnick, K. E., Wigfield, S., Buffa, F. M., Li, J.-L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.056 · Cited by 665
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Fatty Acid Synthase and Cancer: New Application of an Old Pathway
Kuhajda, F. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4673 · Cited by 647
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma
Caro, P., Kishan, A. U., Norberg, E., Stanley, I. A., Chapuy, B., Ficarro, S. B., Polak, K., Tondera, D., Gounarides, J., Yin, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.014 · Cited by 528
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z.-H., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 454
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Cao, Y. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3055 · Cited by 442
Self-citationPericyte–fibroblast transition promotes tumor growth and metastasis
Hosaka, K., Yang, Y., Seki, T., Fischer, C., Dubey, O., Fredlund, E., Hartman, J., Religa, P., Morikawa, H., Ishii, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608384113 · Cited by 415
Self-citationLazar, I., Clement, E., Dauvillier, S., Milhas, D., Ducoux-Petit, M., LeGonidec, S., Moro, C., Soldan, V., Dalle, S., Balor, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0651 · Cited by 387
Mungai, P. T., Waypa, G. B., Jairaman, A., Prakriya, M., Dokic, D., Ball, M. K., & Schumacker, P. T. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05124-11 · Cited by 385
Brâkenhielm, E., Cao, R., & Cao, Y. (2001) · The FASEB Journal · doi:10.1096/fj.01-0028fje · Cited by 334
Self-citationCao, Y. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.008 · Cited by 319
Self-citationHamilton, J. A., & Kamp, F. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2255 · Cited by 314
Forty-Year Journey of Angiogenesis Translational Research
Cao, Y., Arbiser, J., D’Amato, R. J., D’Amore, P. A., Ingber, D. E., Kerbel, R., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 223
Self-citationQian, B.-Z., Zhang, H., Li, J., He, T., Yeo, E.-J., Soong, D. Y. H., Carragher, N. O., Munro, A., Chang, A., Bresnick, A. R., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141555 · Cited by 198
Liu, Y., Zuckier, L. S., & Ghesani, N. V. (2010) · PubMed · Cited by 183
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 180
Yang, X., Zhang, Y., Hosaka, K., Andersson, P., Wang, J., Tholander, F., Cao, Z., Morikawa, H., Tegnér, J., Yang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503500112 · Cited by 161
Self-citationAnti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues
Yang, Y., Zhang, Y., Cao, Z., Ji, H. L., Yang, X., Iwamoto, H., Wahlberg, E., Länne, T., Sun, B., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301331110 · Cited by 143
Self-citationYang, Y., Zhang, Y., Iwamoto, H., Hosaka, K., Seki, T., Andersson, P., Lim, S., Fischer, C., Nakamura, M., Abe, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12680 · Cited by 114
Self-citationOptimizing the Delivery of Cancer Drugs That Block Angiogenesis
Cao, Y., & Langer, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000399 · Cited by 86
Self-citationNardo, G., Favaro, E., Curtarello, M., Moserle, L., Zulato, E., Persano, L., Rossi, E. M. C., Esposito, G., Crescenzi, M., Casanovas, O., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0242 · Cited by 75
Yang, X., Zhang, Y., Yang, Y., Lim, S., Cao, Z., Rak, J. W., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309629110 · Cited by 72
Self-citationMolecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival
Reilly, P. T., & Mak, T. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3281 · Cited by 68
Cao, Y., Zhong, W., & Sun, Y. P. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.001 · Cited by 66
Self-citationHonek, J., Seki, T., Iwamoto, H., Fischer, C., Li, J., Lim, S., Samani, N. J., Zang, J., & Cao, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415825111 · Cited by 61
Self-citationLim, S., Hosaka, K., Nakamura, M., & Cao, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9436 · Cited by 32
Self-citation
Cited by
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Self-citationAspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Yang, E., Wang, X., Gong, Z., Yu, M., Wu, H., & Zhang, D. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00359-5 · Cited by 494
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Jin, H.-R., Wang, J., Wang, Z.-J., Xi, M.-J., Xia, B.-H., Deng, K., & Yang, J.-L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01498-2 · Cited by 481
Wu, H., Han, Y., Rodriguez Sillke, Y., Deng, H., Siddiqui, S., Treese, C., Schmidt, F., Friedrich, M., Keye, J., Wan, J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910698 · Cited by 373
Metadata
- Authors
- Iwamoto, H., Abe, M., Yang, Y., Cui, D., Seki, T., Nakamura, M., Hosaka, K., Lim, S., Wu, J., He, X., Sun, X., Lu, Y., Zhou, Q., Shi, W., Torimura, T., Nie, G., Li, Q., & Cao, Y.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 28
- Issue
- 1
- Pages
- 104-117.e5
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2807145508
- Cited by
- 300
- References
- 40
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.